• Valmet Q2 2026 comparable EBITA rose 6% to EUR 152 million; net sales increased 6% to EUR 1.32 billion.
• Profit for the period more than doubled to EUR 75 million; EPS more than doubled to EUR 0.40.
• Orders received fell 10% to EUR 1.37 billion; order backlog declined 10% to EUR 4.26 billion.
• CEO Thomas Hinnerskov said biomaterial capital orders totaled EUR 501 million, up sequentially, while biomaterial services markets remained soft but stabilizing.
• Guidance reiterated: 2026 net sales seen at the prior-year level; comparable EBITA expected to be at the prior-year level or increase.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valmet Oyj published the original content used to generate this news brief via Cision (Ref. ID: 20260724:BIT:1543:0) on July 24, 2026, and is solely responsible for the information contained therein.